bioMONTR Labs Announces Laboratory Service Agreement With ViiV Healthcare

Press Release (ePRNews.com) - RESEARCH TRIANGLE PARK, N.C. - Jun 25, 2018 - bioMONTR Labs reported today they have entered into a new Laboratory Service Agreement with ViiV Healthcare to provide HIV-1 viral load testing services for a recently announced Phase III study with a two-drug of long-acting, injectable regimen of cabotegravir plus rilpivirine in virally suppressed adults with HIV-1 infection. The ATLAS-2M study is anticipated to enroll more than 1,020 participants.  

Daniel McClernon, president and chief scientific officer for bioMONTR Labs, stated, “We are pleased to provide our proprietary HIV-1 SuperLow single copy assay to assess the efficacy of these investigational medicines. bioMONTR Labs is uniquely positioned to support ongoing and new clinical trials by providing access to our highly specialized molecular test methods.”

Financial terms were not disclosed. 

With our newly expanded capabilities, we are able to provide these important tools on a greater scale and assist novel drug development programs which benefit individuals living with chronic infectious diseases.

Anita M. McClernon

Vice President & Chief Operations Officer

About bioMONTR Labs

bioMONTR Labs is a privately owned, CLIA Certified lab located in Research Triangle Park, North Carolina. The company offers a comprehensive menu of high-complexity, molecular assays as well as other proprietary and esoteric molecular testing.  For more information on the company, its management, test menu and capabilities, please visit www.biomontr.com.

CONTACT DETAiLS:

Anita M. McClernon
Vice President & Chief Operations Officer
Email: amcclernon@biomontr.com
Phone: 1-866-609-3870 ext. 702

Source : bioMONTR Labs
Business Info :
bioMONTR Labs

You may also like this  

DISCLAIMER : If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/services/business mentioned and hereby disclaims any content contained in this press release.

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login